Fox News reporter David Spand joins the latest special report from MDA headquarters in Silver Spring. Improve shot performance in the elderly. Early trials showed that the vaccine produced “adequate” immunity in the elderly, demonstrating the need to refine the product, so it protects all ages. London-based GSK and Paris-based Sanofi now expect the vaccine to be available in the fourth quarter of 2021. “The results of the study did not live up to our expectations,” said Roger Connor, head of GSK Vaccines, in a statement. GSK shows the challenges facing scientists. Researchers in Australia said they would drop their own vaccine candidate on Friday because it gave false positive results to HIV tests. Public health experts say many vaccines will be needed to end the epidemic, which has killed more than 1.5 million people worldwide because the challenges lie in producing and distributing enough to vaccinate billions of people quickly. The vaccine, developed by US pharmaceutical maker Pfizer and German partner Bioendech, is widely approved for use in the UK and a few other countries. A U.S. government advisory panel on Thursday approved the use of the Pfizer vaccine, putting the country one step further from launching its own mass vaccination program. GSK and Sanofi said they were optimistic about the final success of their vaccine because of the positive results of other tests. Pfizer’s Coronavirus VACCINE: What You Need to Know The vaccine has been shown to improve immunity in patients overcoming COVID-19, according to companies. In addition, they reported positive results from a “challenge study” in which non-human animals were deliberately exposed to the virus. “Following these results and the latest encouraging new advance data, we now aim to further improve our candidate to achieve this goal,” said Thomas Triumph, head of Sanobi’s vaccination division. “No pharmaceutical company can develop this alone. The world needs more than one vaccine to fight the infection.” The follow-up tests confirmed that there was no HIV, the researchers said. While it would be possible to re-engineering the vaccine to avoid the problem of false positives, it would have taken longer among infections, they said. The urgent need for the vaccine should be everyone’s priority when it’s a difficult decision to block growth for months, ”said Professor Paul Young, co-chair of the program. Click here to read more stories on Fox Business
Source